Inactive Instrument

Highlights Nanomix Corporation

Stocks

NNMX

US63008H2013

Advanced Medical Equipment & Technology

Highlights

25/23/25	Nanomix Corporation Announces Chief Executive Officer Changes	CI
07/23/07	Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
25/23/25	Nanomix Corporation Appoints Christopher R. Hetterly as Chief Financial Officer	CI
29/22/29	Nanomix Corporation Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy	CI
15/22/15	Nanomix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
09/22/09	Nanomix Corporation Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd	CI
04/22/04	Nanomix Corporation Enters into Multi-Country Distribution Agreement for the Elab System with Mast Group Limited	CI
20/22/20	Nanomix Corporation Announces Distribution Agreement with Diaclinic SpA	CI
12/22/12	Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Ips Genomix S.A.L. in the Middle East	CI
02/22/02	Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies	CI
23/22/23	Nanomix Enters into Distribution Agreement for the Elab System and Future New Products with Bioasia Pte Ltd in Singapore	CI
16/22/16	Nanomix Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
21/22/21	Nanomix Corporation Announces Distribution Agreement for the eLab System with Biotron Ltd. in Israel	CI
22/22/22	Nanomix Corporation Initiates New Clinical Study for the eLab S1 Panel	CI
14/22/14	Nanomix Corporation Receives IVDR Certification for the eLab Analyzer	CI
26/22/26	Nanomix Granted Ce Mark for Elab S1 Assay Panel for Whole Blood Samples	CI
17/22/17	Nanomix Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
09/21/09	Nanomix Announces UK MHRA Registration for New Point of Care System	CI
02/21/02	Nanomix Corporation Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19	CI
28/21/28	Boston Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021	CI
28/21/28	Boston Therapeutics, Inc. Announces Audited Consolidated Earnings Results for the Full Year Ended December 31, 2020	CI
15/21/15	Boston Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
04/21/04	Nanomix, Inc. completed the acquisition of Boston Therapeutics, Inc. in a reverse merger transaction on June 4, 2021.	CI
23/21/23	Boston Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
02/21/02	Nanomix, Inc. entered into an Agreement to acquire Boston Therapeutics, Inc. in a reverse merger transaction.	CI